MedPath

Single and multiple doses study of DS-5565 in healthy Chinese subjects

Phase 1
Completed
Conditions
Healthy volunteers
Registration Number
JPRN-jRCT1080223624
Lead Sponsor
DAIICHI SANKYO CO., LTD.
Brief Summary

DS-5565 was safe and well-tolerated at single doses of 5 mg to 15 mg and at multiple doses of up to 15 mg in healthy Chinese subjects.

Detailed Description

Not available

Recruitment & Eligibility

Status
completed
Sex
All
Target Recruitment
54
Inclusion Criteria

1)Healthy Chinese
2)Aged 18 years to 45 years (inclusive), at the time of informed consent
3)Body weight of female >= 45 kg, male >= 50 kg, and a BMI in the range of 19.0 kg/m2 to 26.0 kg/m2 (inclusive) at screening

Exclusion Criteria

1)Hypersensitivity or idiosyncratic reactions to a drug (such as penicillin allergy)
2)Presence or history of any drug abuse or of alcohol abuse etc.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
safety<br>pharmacokinetics<br>Safety and pharmacokinetics
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath